Impact of alternative treatment approach for cerebral toxoplasmosis among HIV/AIDS patients from a resourcepoor setting in Burkina Faso

• Autorzy: Bamba S. , Zoungrana J. , Nikiema Z. , Sondo A.K. , Ndiaye J.-L. , Bretagne S.
• Języki publikacji: EN

Abstrakty

EN

Cerebral toxoplasmosis is caused by the protozoan Toxoplasma gondii because of reactivation of latent tissue cysts in the Acquired Immunodeficiency Syndrome (AIDS) patients with severe immunosuppression. The objective of this study was to evaluate the benefit of co-trimoxazole in presumptive and prevention of cerebral toxoplasmosis in Human Immunodeficiency Virus (HIV)/AIDS patients at Bobo-Dioulasso Hospital in Burkina Faso from June 2012 to October 2014. ELISA and ELFA were performed on serum for the quantitative determination of IgG and IgM anti-T. gondii, respectively. The seroprevalence of toxoplasmosis was 29.3%. No IgM antibodies for T. gondii were found. Six patients with Toxoplasma-specific antibodies presented cerebral toxoplasmosis. All patients were infected by HIV-1 with the median of CD4+ T lymphocytes at 141 cells/μl. No patient was under antiretroviral therapy. No case of cerebral toxoplasmosis was noted in patients receiving co-trimoxazole in prevention. Presumptive treatment of cerebral toxoplasmosis with co-trimoxazole was effective in all patients with a significant clinical improvement in 83.3%. These results attest the benefit of cotrimoxazole in cerebral toxoplasmosis treatment in countries where drug resources are limited when sulfadiazine is not available. Ours finding highlight the importance of establishing toxoplasmosis chemoprophylaxis to HIV with severe immunosuppression patients and positive Toxoplasma serology.

• Wydawca: -
• Czasopismo: Annals of Parasitology
• Rocznik: 2017
• Tom: 63
• Numer: 3
• Opis fizyczny: p.173-181,fig.,ref.

Twórcy

autor

Bamba S.

• Laboratory of Parasitology-Mycology, Higher Institute of Health Sciences, Polytechnic University, Rue Alwata Diawara, Bobo-Dioulasso, BP 1091, Burkina Faso

autor

Zoungrana J.

• Department of Infectious Diseases, Higher Institute of Health Sciences, Polytechnic University, Rue Alwata Diawara, Bobo-Dioulasso, BP 1091, Burkina Faso

autor

Nikiema Z.

• Radiology and Medical Imaging, Higher Institute of Health Sciences, Polytechnic University, Rue Alwata Diawara, Bobo-Dioulasso, BP 1091, Burkina Faso

autor

Sondo A.K.

• Department of Infectious Diseases, Faculty of Health Sciences, University Teaching Hospital, 1190 Rue Phillip Zinda, Ouagadougou, PB 540, Burkina Faso

autor

Ndiaye J.-L.

• Laboratory of Parasitology-Mycology, Faculty of Medicine and Pharmacy, University of Cheikh Anta Diop, Fan 7600, BP 5100, Dakar, Senegal

autor

Bretagne S.

• Laboratory of Parasitology-Mycology, Saint-Louis Hospital, 1 Avenue Claude-Vellefaux, 75010 Paris, France

Bibliografia

• [1] de Oliveira G.B, da Silva M.A.L., Wanderley L.B., da Cunha Correia C., Ferreira E.C.B., de Medeiros Z.M., Filho J.L.L., de Melo F.L., de Araújo P.S.R., Santos A.H.C.M. 2016. Cerebral toxoplasmosis in patients with acquired immune deficiency syndrome in the neurological emergency department of a tertiary hospital. Clinical Neurology and Neurosurgery 150: 23-26. doi:10.1016/j.clineuro.2016.08.014
• [2] Coelho L.E., Cardoso S.W., Amancio R.T., Moreira R.I., Ribeiro S.R., Coelho A.B., Campos D.P., Veloso V.G., Grinsztejn B., Luz P.M. 2016. Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil. BMC Infectious Diseases 16: 134. doi:10.1186/s12879-016-1462-x
• [3] Schneider M.M.E., Hoepelman A.I.M., Eeftinck Schattenkerk J.K.M., Nielsen T.L., van der Graaf Y., Frissen J.P.H.J., van der Ende I.M.E., Kolsters A.F.P., Borleffs J.C. C., the Dutch AIDS Treatment Group. 1992. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. New England Journal of Medicine 327: 1836-1841. doi:10.1056/nejm199212243272603
• [4] Hardy W.D., Feinberg J., Finkelstein D.M., Power M.E., He W., Kaczka C., Frame P.T., Holmes M., Waskin H., Fass R.J., Powderly W.G., Steigbigel R.T., Zuger A., Robert S. Holzman R.S. 1992. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome - AIDS Clinical Trials Group Protocol 021. New England Journal of Medicine 327: 1842-1848. doi:10.1056/nejm199212243272604
• [5] Millogo A., Ki-Zerbo G.A., Traoré W., Sawadogo A.B., Ouédraogo I., Péghini M. 2000. Sérologie toxoplasmique chez les patients infectés par le VIH et suspects de toxoplasmose cérébrale au centre hospitalier de Bobo-Dioulasso, Burkina-Faso. [Toxoplasma serology in HIV-infected patients at Bobo-Dioulasso hospital (Burkina Faso)]. Bulletin de la Société de Pathologie Exotique 93: 17-19 (in French with summary in English).
• [6] Ministère de la santé (MS) du Burkina Faso. 2015. Burkina Faso. Comité ministériel de lutte contre le VIH/SIDA au Burkina Faso. Normes et protocoles de prise en charge médicale des personnes vivant avec le VIH au Burkina Faso., 3ème edition: 148.
• [7] Cimon B., Marty P., Morin O., Bessières M.-H., Marx-Chemla C., Gay-Andrieu F., Thulliez P. 1998. Specificity of low anti-Toxoplasma IgG titers with IMx and AxSYM Toxo IgG assays. Diagnostic Microbiology and Infectious Disease 32: 65-67. http://dx.doi.org/10.1016/S0732-8893(98)00060-1
• [8] De Souza G.F., Carvalho D., Pedrosa W., Franck J., Piarroux R. 2012. Analytical validation of anti-Toxoplasma IgG immunoassays. Brazilian Journal of Infectious Diseases 16: 574-576. https://doi.org/10.1016/j.bjid.2012.07.014
• [9] Reis M.M., Tessaro M.M., D’Azevedo P.A. 2006. Toxoplasma-IgM and IgG-avidity in single samples from areas with a high infection rate can determine the risk of mother-to-child transmission. Revista do Instituto de Medicina Tropical de São Paulo 48: 93-98. http://dx.doi.org/10.1590/S0036-46652006000200007
• [10] Ondounda M., Ilozue C., Magne C. 2016. Cerebromeningeal infections in HIV-infected patients: a study of 116 cases in Libreville, Gabon. African Health Sciences 16: 603-610. http://dx.doi.org/10.4314/ahs.v16i2.31
• [11] Shalaka N.S., Garred N.A., Zeglam H.T., Awasi S.A., Abukathir L.A., Altagdi M.E., Rayes A.A. 2015. Clinical profile and factors associated with mortality in hospitalized patients with HIV/AIDS: a retrospective analysis from Tripoli Medical Centre, Libya, 2013. Eastern Mediterranean Health Journal 21: 635-646.
• [12] Yohanes T., Debalke S., Zemene E. 2014. Latent Toxoplasma gondii infection and associated risk factors among HIV-infected individuals at Arba Minch Hospital, South Ethiopia. AIDS Research and Treatment 2014: 652941. doi:10.1155/2014/652941
• [13] Shamilah H., Lokman-Hakim S., Nooerazian M.Y., Malkith K., Yusri M.Y. 2001. Seroprevalence of Toxoplasma gondii antibodies in HIV positive and negative patients using the immunofluorescence antibody test (IFAT) methods. Tropical Biomedicine 18: 137-141.
• [14] Nissapatorn V., Kamarulzaman A., Init I, Tan L.H., Rohela M., Norliza A., Chan L.L., Latt H.M., Annuar A.K., Quek K.F. 2002. Seroepidemiology of toxoplasmosis among HIV infected patients and healthy blood donors. Medical Journal of Malaysia 57: 304-310.
• [15] Montoya J.G. 2002. Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. Journal of Infectious Diseases 15 (Suppl. 1): S73-S82. https://doi.org/10.1086/338827
• [16] Derouin F., Thulliez P., Garin Y.J.F. 1991. Intérêt et limites de la sérologie de la toxoplasmose chez les sujets VIH+. Pathologie Biologie 39: 255-259 (in French).
• [17] Robert-Gangneux F., Dardé M.-L. 2012. Epidemiology of and diagnostic strategies for toxoplasmosis. Clinical Microbiology Reviews 25: 264-296. doi:10.1128/cmr.05013-11
• [18] Sukthana Y., Mahittikorn A., Wickert H., Tansuphaswasdikul S. 2012. A promising diagnostic tool for toxoplasmic encephalitis: tachyzoite/bradyzoite stage-specific RT-PCR. International Journal of Infectious Diseases 6: e279-e284. http://dx.doi.org/10.1016/j.ijid.2011.12.009
• [19] Yoganathan K. 2009. A “brain tumor” in an intravenous drug abuser. International Journal of General Medicine 2: 73-75. https://doi.org/10.2147/ijgm.s4826
• [20] Mathews C., Barba D., Fullerton S.C. 1995. Early biopsy versus empiric treatment with delayed biopsy of non-responders in suspected HIV-associated cerebral toxoplasmosis: a decision analysis. AIDS 9: 1243-1250.
• [21] Landrith T.A., Harris T.H., Wilson E.H. 2015. Characteristics and critical function of CD8+ T cells in the Toxoplasma-infected brain. Seminars in Immunopathology 37: 261-270. doi:10.1007/s00281-015-0487-3
• [22] Derouin F., Leport C., Pueyo S., Morlat P., Letrillart B., Chêne G., Ecobichon J.-L., Luft B., Aubertin J., Hafner R., Vildé J.-L., Salamon R., ANRS 005ACTG 154 Trial Group. 1996. Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. AIDS 10: 1521-1527.
• [23] Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. 2017. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf
• [24] Abgrall S., Rabaud C., Costagliola D., the Clinical Epidemiology Group of the French Hospital Database on HIV. 2001. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clinical Infectious Diseases 33: 1747-1755. https://doi.org/10.1086/322622
• [25] Kodym P., Malý M., Beran O., Jilich D., Rozsypal H., Machala L., Holub M. 2015. Incidence, immunological and clinical characteristics of reactivation of latent Toxoplasma gondii infection in HIV-infected patients. Epidemiology and Infection 143: 600-607. https://doi.org/10.1017/s0950268814001253
• [26] Alapatt J.P., Kutty R.K., Jose B., Gopi P.A. 2009. Case of cerebral toxoplasmosis in a pregnant nonimmunocompromised patient. Neurologia i Neurochirurgia Polska 43: 391-395.
• [27] Hellerbrand C., Goebel F.D., Disko R. 1996. High predictive value of Toxoplasma gondii IgG antibody levels in HIV-infected patients for diagnosis of cerebral toxoplasmosis. European Journal of Clinical Microbiology and Infectious Diseases 15: 869-872. doi:10.1007/bf01691219
• [28] Cissoko Y., Seydi M., Fortes Deguenonvo L., Attinssounon A.C., Diop Nyafouna S.A., Manga N.M., Dia Badiane N.D., Tidiane N.C., Soumare M., Diop B.M, Sow P.S. 2013. Profil actuel de la toxoplasmose cérébrale en milieu hospitalier à Dakar [Current profile of cerebral toxoplasmosis in a hospital setting in Dakar]. Médecine et Santé Tropicales 23: 197-201 (in French with summary in English). doi:10.1684/mst.2013.0179
• [29] Jarvis J.N., Boulle A., Loyse A., Bicanic T., Rebe K., Williams A., Harrison T.S., Meintjes G. 2009. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS 23: 1182-1183. doi:10.1097/qad.0b013e32832be0fc
• [30] Deepak M., Basavaprabhu A., Soundarya M. 2015. Multiple intracerebral lesions in a young male. African Health Sciences 15: 1045-1048. http://dx.doi.org/10.4314/ahs.v15i3.47
• [31] Goswami R.P., Goswami R.P., Rahman M., Ray Y., Tripathi S.K. 2015. Alternative treatment approach to cerebral toxoplasmosis in HIV/AIDS: experience from a resource-poor setting. International Journal of STD & AIDS 26: 864-869. https://doi.org/10.1177/0956462414560594

Identyfikatory

DOI

10.17420/ap6303.103